Neurogene NGNE
Price chart
Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.
Community Sentiment on NGNE
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Strategy Backtest
Pick a strategy above and run the backtest to see its simulated performance on NGNE.
Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.
NGNE at a glance
Shares of Neurogene are down 1.33% at $25.31. The company is worth $506.49M, number 3648 out of 3753 on our list.
The stock's 52-week band runs $15.93 to $43.66, and the latest print sits 42.0% under the top end of it. Holders are behind 5.4% over twelve months, and down 30.8% across the last three months.
On the chart it has slipped under both the 50-day ($29.46) and 200-day ($28.02) moving averages; RSI is 45, and the last 30 sessions moved at roughly 90% annualized volatility.
In the quarter ended Jun 2026 the company brought in $0.00 of revenue, and a net loss of $34.49M.
8 analysts follow the stock and the average call is "buy". The mean target, $80.17, sits 216.8% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
BeStock Grade
Composite of 3 factors below, ranked against the 3741 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Trading closer to its 52-week high than most peers scores higher.
8 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
BeStock Momentum
NGNE is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-12-28, the strategy has returned 437.6% (203.8% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.
Price forecast
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $80.17, 216.8% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $26.56, so shares trade 4.7% below that estimate. On earnings multiple, it sits in the 35th percentile of its own five-year valuation range (cheaper than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Performance
Price return over each window, from adjusted daily and weekly closes
Technical signals
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -0.4% | Bearish |
| Price vs 50-day average | -14.1% | Bearish |
| Price vs 200-day average | -9.7% | Bearish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 44.8 | Bearish |
| MACD (12,26,9) | -0.52 | Bullish |
| Bollinger band position | 49% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Key statistics
Quote as of Nov 6, 2026 8:20 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
How NGNE ranks on BeStock
Ranks are among the 3,741 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
NGNE stock: common questions
How is Neurogene stock doing today?
$25.31 is the latest print for NGNE, a move of -1.33% against yesterday's close of $25.65. Today's low and high so far: $24.68 and $27.26.
What is NGNE worth in total?
Equity value comes to $506.49M at the current price. By that measure it is number 3648 of the 3753 names in our coverage.
Where does NGNE sit in its 52-week range?
The year's floor is $15.93 and the ceiling $43.66. Shares are 42.0% away from that ceiling.
Does NGNE send cash back through a dividend?
Our data shows no dividend paid by Neurogene over the trailing twelve months.
Do Wall Street analysts like NGNE?
Of 8 analysts, 100% say buy, 0% hold and 0% sell. Price targets average $80.17, with the most cautious at $46.00 and the most optimistic at $166.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on NGNE.
Sign in to join the discussion.